View in EDS

High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC.

Saved in:
Bibliographic Details
Title: High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC.
Authors: Frigola J; Thoracic Cancers Translational Genomics Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Clinical Research Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Carbonell C; Thoracic Cancers Translational Genomics Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Clinical Research Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Irazno P; Clinical Research Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain., Pardo N; Clinical Research Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain., Callejo A; Clinical Research Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain., Cedres S; Clinical Research Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain., Martinez-Marti A; Clinical Research Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain., Navarro A; Clinical Research Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain., Soleda M; Thoracic Cancers Translational Genomics Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Clinical Research Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Jimenez J; Molecular Oncology Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Hernandez-Losa J; Department of Pathology, Vall d'Hebron University Hospital, Barcelona, Spain., Vivancos A; Cancer Genomics Laboratory, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Felip E; Thoracic Cancers Translational Genomics Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain ramat@vhio.net efelip@vhio.net.; Clinical Research Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain., Amat R; Thoracic Cancers Translational Genomics Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain ramat@vhio.net efelip@vhio.net.; Clinical Research Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Source: Journal for immunotherapy of cancer [J Immunother Cancer] 2022 Apr; Vol. 10 (4).
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Print Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35477861
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Frigola+J%22">Frigola J</searchLink>; Thoracic Cancers Translational Genomics Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Clinical Research Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Carbonell+C%22">Carbonell C</searchLink>; Thoracic Cancers Translational Genomics Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Clinical Research Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Irazno+P%22">Irazno P</searchLink>; Clinical Research Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Pardo+N%22">Pardo N</searchLink>; Clinical Research Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Callejo+A%22">Callejo A</searchLink>; Clinical Research Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Cedres+S%22">Cedres S</searchLink>; Clinical Research Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Martinez-Marti+A%22">Martinez-Marti A</searchLink>; Clinical Research Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Navarro+A%22">Navarro A</searchLink>; Clinical Research Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Soleda+M%22">Soleda M</searchLink>; Thoracic Cancers Translational Genomics Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Clinical Research Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Jimenez+J%22">Jimenez J</searchLink>; Molecular Oncology Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Hernandez-Losa+J%22">Hernandez-Losa J</searchLink>; Department of Pathology, Vall d'Hebron University Hospital, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Vivancos+A%22">Vivancos A</searchLink>; Cancer Genomics Laboratory, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Felip+E%22">Felip E</searchLink>; Thoracic Cancers Translational Genomics Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain ramat@vhio.net efelip@vhio.net.; Clinical Research Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Amat+R%22">Amat R</searchLink>; Thoracic Cancers Translational Genomics Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain ramat@vhio.net efelip@vhio.net.; Clinical Research Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101620585%22">Journal for immunotherapy of cancer</searchLink> [J Immunother Cancer] 2022 Apr; Vol. 10 (4).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22BMJ+Publishing+Group+Ltd%22">BMJ Publishing Group Ltd </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101620585 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>2051-1426 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220511426%22">20511426 </searchLink><i>NLM ISO Abbreviation: </i>J Immunother Cancer <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35477861
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1136/jitc-2021-004197
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Frigola J
      – PersonEntity:
          Name:
            NameFull: Carbonell C
      – PersonEntity:
          Name:
            NameFull: Irazno P
      – PersonEntity:
          Name:
            NameFull: Pardo N
      – PersonEntity:
          Name:
            NameFull: Callejo A
      – PersonEntity:
          Name:
            NameFull: Cedres S
      – PersonEntity:
          Name:
            NameFull: Martinez-Marti A
      – PersonEntity:
          Name:
            NameFull: Navarro A
      – PersonEntity:
          Name:
            NameFull: Soleda M
      – PersonEntity:
          Name:
            NameFull: Jimenez J
      – PersonEntity:
          Name:
            NameFull: Hernandez-Losa J
      – PersonEntity:
          Name:
            NameFull: Vivancos A
      – PersonEntity:
          Name:
            NameFull: Felip E
      – PersonEntity:
          Name:
            NameFull: Amat R
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 04
              Text: 2022 Apr
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 2051-1426
          Numbering:
            – Type: volume
              Value: 10
            – Type: issue
              Value: 4
          Titles:
            – TitleFull: Journal for immunotherapy of cancer
              Type: main
ResultId 1